Syndax Pharmaceuticals Inc (SNDX) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
SNDX currently has 88.3M outstanding shares. with minimal authorized share overhang for future dilution. The company has minimally diluted shareholders by 3.46% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Apr 30, 2026 |
10-Q filing | 88.3M shares outstanding |
88M | 0 |
| Nov 03, 2025 |
10-Q filing | 86.6M shares outstanding |
87M | 0 |
| Aug 04, 2025 |
10-Q filing | 86.3M shares outstanding |
86M | 0 |
| May 05, 2025 |
10-Q filing | 86.2M shares outstanding |
86M | 0 |
| Mar 03, 2025 |
10-K filing | 85.6M shares outstanding |
86M | 0 |
| Nov 05, 2024 |
10-Q filing | 85.4M shares outstanding |
85M | 0 |
| Aug 01, 2024 |
10-Q filing | 85.3M shares outstanding |
85M | 0 |
| May 08, 2024 |
10-Q filing | 85.2M shares outstanding |
85M | 0 |
| Feb 27, 2024 |
10-K filing | 85.0M shares outstanding |
85M | 0 |
| Nov 02, 2023 |
10-Q filing | 69.9M shares outstanding |
70M | 0 |
| Aug 03, 2023 |
10-Q filing | 69.6M shares outstanding |
70M | 0 |
| May 08, 2023 |
10-Q filing | 69.4M shares outstanding |
69M | 0 |
| Feb 28, 2023 |
10-K filing | 0.1M shares outstanding |
68K | 51M |
| Nov 03, 2022 |
10-Q filing | 60.7M shares outstanding |
61M | 0 |
| Aug 08, 2022 |
10-Q filing | 60.2M shares outstanding |
60M | 0 |
| May 09, 2022 |
10-Q filing | 56.2M shares outstanding |
56M | 0 |
| Mar 01, 2022 |
10-K filing | 53.6M shares outstanding |
54M | 0 |
| Nov 15, 2021 |
10-Q filing | 49.4M shares outstanding |
49M | 2.1M |
| Aug 09, 2021 |
10-Q filing | 48.6M shares outstanding |
49M | 2.9M |
| May 11, 2021 |
10-Q filing | 48.2M shares outstanding |
48M | 3.2M |
| Mar 22, 2021 |
S-3 filing: The filing is an S-3 registration statement for the potential offering of common stock, preferred stock, and debt securities from time to time, including an at-the-market offering of common stock through Cowen with an aggregate offering price of up to $75,000,000. |
48M | 3.6M |
| Mar 12, 2021 |
10-K filing | 48.2M shares outstanding |
48M | 0 |
| Nov 05, 2020 |
10-Q filing | 40.9M shares outstanding |
41M | 0 |
| Aug 06, 2020 |
10-Q filing | 38.5M shares outstanding |
39M | 0 |
| May 07, 2020 |
10-Q filing | 36.1M shares outstanding |
36M | 0 |
| May 04, 2020 |
8-K filing: Syndax Pharmaceuticals, Inc. entered into an underwriting agreement for the issuance and sale of 5,555,556 shares of common stock at a price of $18.00 per share, with an option for the underwriters to purchase an additional 833,333 shares. ($93.7M proceeds) |
30M | 0 |
| Mar 05, 2020 |
10-K filing | 30.2M shares outstanding |
30M | 0 |